You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

CLARITIN REDITABS Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Claritin Reditabs, and what generic alternatives are available?

Claritin Reditabs is a drug marketed by Bayer Healthcare Llc and is included in two NDAs.

The generic ingredient in CLARITIN REDITABS is loratadine. There are thirty-nine drug master file entries for this compound. One hundred and forty-nine suppliers are listed for this compound. Additional details are available on the loratadine profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Claritin Reditabs

A generic version of CLARITIN REDITABS was approved as loratadine by PLD ACQUISITIONS LLC on January 21st, 2003.

  Try a Trial

Drug patent expirations by year for CLARITIN REDITABS
Recent Clinical Trials for CLARITIN REDITABS

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Merck Sharp & Dohme Corp.
Ranbaxy Laboratories LimitedN/A

See all CLARITIN REDITABS clinical trials

US Patents and Regulatory Information for CLARITIN REDITABS

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bayer Healthcare Llc CLARITIN REDITABS loratadine TABLET, ORALLY DISINTEGRATING;ORAL 021993-001 Dec 12, 2006 OTC Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Bayer Healthcare Llc CLARITIN REDITABS loratadine TABLET, ORALLY DISINTEGRATING;ORAL 020704-002 Nov 27, 2002 OTC Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for CLARITIN REDITABS

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bayer Healthcare Llc CLARITIN REDITABS loratadine TABLET, ORALLY DISINTEGRATING;ORAL 020704-002 Nov 27, 2002 ⤷  Try a Trial ⤷  Try a Trial
Bayer Healthcare Llc CLARITIN REDITABS loratadine TABLET, ORALLY DISINTEGRATING;ORAL 020704-002 Nov 27, 2002 ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for CLARITIN REDITABS

See the table below for patents covering CLARITIN REDITABS around the world.

Country Patent Number Title Estimated Expiration
Finland 853675 ⤷  Try a Trial
Denmark 173765 ⤷  Try a Trial
South Korea 850000744 ⤷  Try a Trial
Germany 3573600 ⤷  Try a Trial
Italy 1158951 PROCEDIMENTO PER PREPARARE CONFEZIONI CHE CONTENGONO UNO O PIU' ARTICOLO SAGOMATI CHE SUPPORTANO COMPOSTI CHIMICI E CONFEZIONI COSI' PREPARATE ⤷  Try a Trial
Japan H0859657 PIPERIDIDENEDIHYDRODIBENZO(A,B)CYCLOHEPTENE COMPOUND AND MEDICINE COMPOSITION CONTAINING SAME ⤷  Try a Trial
Malaysia 8700761 NOVEL ANTIHISTAMINES PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for CLARITIN REDITABS

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0152897 C00152897/01 Switzerland ⤷  Try a Trial FORMER REPRESENTANTIVE: E. BLUM AND CO. PATENTANWAELTE, CH
1110543 SPC/GB08/005 United Kingdom ⤷  Try a Trial SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB08/005 GRANTED TO MERCK SHARP + DOHME CORP. IN RESPECT OF THE PRODUCT DESLORATADINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN COMBINATION WITH PSEUDOEPHEDRINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6322 DATED 21 JULY 2010 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 31 JULY 2022.
0152897 2001C/013 Belgium ⤷  Try a Trial PRODUCT NAME: DESLORATADINE; REGISTRTION NO/DATE: EU/1/00/160/010 20010115
0152897 SPC/GB01/012 United Kingdom ⤷  Try a Trial PRODUCT NAME: DESLORATADINE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK EU/1/00/157/001-013 20010115; UK EU/1/00/158/001-013 20010115; UK EU/1/00/159/001-013 20010115; UK EU/1/00/160/001-013 20010115; UK EU/1/00/161/001-013 20010115
1110543 08C0004 France ⤷  Try a Trial PRODUCT NAME: DESLORATADINE; PSEUDOEPHEDRINE SULFATE; REGISTRATION NO/DATE: EU/1/07/399/001 20070730
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.